HOME >> BIOLOGY >> NEWS
Green tea extract shows promise as an anti-cancer agent, UCLA study finds

A study on bladder cancer cells lines showed that green tea extract has potential as an anti-cancer agent, proving for the first time that it is able to target cancer cells while leaving healthy cells alone.

The study, published in the Feb. 15, 2005 issue of the peer-reviewed journal Clinical Cancer Research, also uncovered more about how green tea extract works to counteract the development of cancer, said JianYu Rao, a Jonsson Cancer Center member, an associate professor of pathology and laboratory medicine and the study's senior author.

"Our study adds a new dimension in understanding the mechanisms of green tea extract," Rao said. "If we knew exactly how it works to inhibit the development of cancer, we could figure out more precisely which bladder cancer patients might benefit from taking it."

Numerous epidemiologic and animal studies have suggested that green tea extract provides strong anti-cancer effects in several human cancers, including bladder cancer. It has been shown to induce death in cancer cells, as well as inhibiting the development of an independent blood supply that cancers develop so they can grow and spread.

In the UCLA study, which brought together researchers from UCLA's Jonsson Cancer Center, School of Public Health, Center for Human Nutrition and the departments of Pathology and Laboratory Medicine, Surgery, Urology and Epidemiology, scientists were able to show that green tea extract interrupts a process that is crucial in allowing bladder cancer to become invasive and spread to other areas of the body.

Green tea extract affects actin remodeling, an event associated with cell movement. When a human moves, the muscles and skeletal structure operate together to facilitate that movement. For cancer to grow and spread, the malignant cells must be able to move. The cell movement depends on actin remodeling, which is carefully regulated by complex signaling pathways, including the Rho pathway. When actin
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
15-Feb-2005


Page: 1 2 3

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. Greenlands ancient forests shed light on stability of ice sheet
3. Green Junta
4. Green Nanotechnology: Its Easier Than You Think
5. Green tea and COX-2 inhibitors combine to slow growth of prostate cancer
6. Stevens Center for Science Writings honors Edward O. Wilson with Green Book Award
7. Green payments are the future of agricultural support
8. Green Chemical Reactor Engineering -- XI
9. Climate changes are linked between Greenland and the Antarctic
10. Green plants share bacterial toxin
11. Mary Frances Lyon to receive Rockefellers Pearl Meister Greengard Prize

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Green tea extract shows promise anti cancer agent UCLA study finds

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: